The Treatment Landscape: What Failed, What Works, and How to Sequence It

In this segment, our panel puts the current treatment landscape for metastatic uveal melanoma into historical context, walking through the long series of agents that failed to move the needle before the recent shift in what is achievable for these patients. You will hear why targeted therapies and checkpoint inhibitors largely disappointed in this disease, and what it means that a systemic therapy has now demonstrated an overall survival advantage for the first time. The panel also discusses the growing role of liver-directed therapies including percutaneous hepatic perfusion, explains what the prospective data now show, and addresses the central clinical challenge of how to sequence and combine systemic and regional approaches to get the most out of the options now available.